The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma.
The prognostic landscape of tumor-infiltrating immune cells in lung squamous cell carcinoma.
复制标题
肺鳞状细胞癌肿瘤浸润免疫细胞的预后情况
DOI：
10.21037/atm-21-1852
复制
发表时间：
2021-05
影响因子：
--
通讯作者：
Li J
中科院分区：
文献类型：
--
作者：
Guo L;Yi J;Liu M;Li J
研究背景探索新的生物标志物和有效的治疗策略可以改善肺鳞癌的预后。肿瘤浸润免疫细胞（TIC）在实体瘤中的预后价值已被广泛研究。然而，TIC在非小细胞肺癌（NSCLC），特别是LUSC预后中的作用仍不清楚，应进行系统研究。方法回顾性研究分析了490例LUSC患者的免疫相关转录谱，来自癌症基因组图谱（TCGA）队列。使用CIBERSORT方法，评估并检查TIC与LUSC总生存期（OS）的相关性。结果27例TIA中，14例与LUSC的预后相关。一种新的预后模型，其特征在于较少的记忆B细胞和更多的中央记忆CD8 T细胞，调节性T细胞（TcR）和浆细胞样树突状细胞（pDC）浸润预测低OS LUSC具有较高的准确性。在训练队列中，1年、3年和5年的曲线下面积（AUC）分别为0.95、0.98和0.96。该结果在验证队列中得到进一步验证，其中1年、3年和5年AUC分别为0.95、0.98和0.95。结论本研究为LUSC的免疫治疗提供了更有效的预后指标和潜在的治疗靶点。
Background Exploring novel biomarkers and developing effective therapeutic strategies can improve the prognosis of lung squamous cell carcinoma (LUSC) in the future. The prognostic value of tumor-infiltrating immune cells (TICs) in solid tumors has been extensively studied. However, the landscape of TICs involved in the prognosis of non-small cell lung cancer (NSCLC), especially in LUSC, remains unclear and should be systematically investigated. Methods This retrospective study analyzed the immune-related transcriptional profiles of 490 LUSC patients from The Cancer Genome Atlas (TCGA) cohort. Using the CIBERSORT method, TICs were evaluated and examined for their association with overall survival (OS) in LUSC. Results Out of the 27 TICs, 14 were correlated with prognosis in LUSC. A novel prognostic model characterized by fewer memory B cells and more central memory CD8 T cells, regulatory T cells (Tregs), and plasmacytoid dendritic cell (pDC) infiltration predicted poor OS in LUSC with high accuracy. The 1-, 3-, and 5-year areas under the curve (AUC) were 0.95, 0.98, and 0.96, respectively, in the training cohort. This finding was further validated in the validation cohort, where the 1-, 3-, and 5-year AUCs were 0.95, 0.98, and 0.95, respectively. Conclusions These findings may provide more effective prognostic biomarkers and potential therapeutic targets for the immunotherapy of LUSC.
登录
查看更多内容
影响因子：
15.9
作者：
Chockley, Peter J.;Chen, Jun;Keshamouni, Venkateshwar G.
通讯作者：
Keshamouni, Venkateshwar G.
影响因子：
7.5
作者：
Liu, Xinyan;Wu, Shucai;Hou, Zhihua
通讯作者：
Hou, Zhihua
影响因子：
11.2
作者：
Lim S;Phillips JB;Madeira da Silva L;Zhou M;Fodstad O;Owen LB;Tan M
通讯作者：
Tan M
影响因子：
3.7
作者：
Mulder NJ;Adebiyi E;Adebiyi M;Adeyemi S;Ahmed A;Ahmed R;Akanle B;Alibi M;Armstrong DL;Aron S;Ashano E;Baichoo S;Benkahla A;Brown DK;Chimusa ER;Fadlelmola FM;Falola D;Fatumo S;Ghedira K;Ghouila A;Hazelhurst S;Isewon I;Jung S;Kassim SK;Kayondo JK;Mbiyavanga M;Meintjes A;Mohammed S;Mosaku A;Moussa A;Muhammd M;Mungloo-Dilmohamud Z;Nashiru O;Odia T;Okafor A;Oladipo O;Osamor V;Oyelade J;Sadki K;Salifu SP;Soyemi J;Panji S;Radouani F;Souiai O;Tastan Bishop Ö;H3ABioNet Consortium, as members of the H3Africa Consortium
通讯作者：
H3ABioNet Consortium, as members of the H3Africa Consortium
影响因子：
4.6
作者：
Shang B;Liu Y;Jiang SJ;Liu Y
通讯作者：
Liu Y